First AD

Second AD

Perspectives of IMerge Study

Please comment on which patients you would consider 2L imetelstat for patients with LR-MDS.

Please provide a summary of the IMerge study, evaluating imetelstat in patients that R/R to ESAs in LR-MDS. (

Platzbecker U, Santini V, Fenaux P, et al. Lancet. 2024;403(10423):249-260.

Dr Komrokji: How does the latest follow up from the IMergestudy support the use of imetelstat in patients with LR-MDS?

Clinical

® Clinical Focus page includes a listing of all specialities covered across  OncLive.com, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, hematologic malignancies, and gynecologic cancers. Each individual specialty page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research.


OncLive Peer Exchange® 

® Peer Exchange video program comprises lively expert panel discussions feature peer-to-peer exchanges providing authoritative insights, opinions, and perspectives on important issues facing today’s health care professionals. Episodes focus on updates and insights across solid and hematologic malignancies, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecological cancers, and hematologic malignancies. 

Video Series

Lower-Risk Myelodysplastic Syndromes (LR-MDS): Highlights from EHA 2024 

Peer Exchange

Medical professionals deliberate on patient selection criteria for second-line imetelstat treatment in lower-risk myelodysplastic syndromes, incorporating findings from the IMerge study into their considerations. 